289 results about "Melanoma" patented technology

The invention discloses an application of a polysaccharide monomer separated from schisandra chinensis in preparation of a PD-L1 + TAMs activator. A large number of experiments show that the polysaccharide monomer schisanan B separated from schisandra chinensis can effectively activate PD-L1 + TAMs cell subsets, so that the phagocytosis of TAMs is enhanced, and the proliferation of tumor cells is inhibited; therefore, it is determined that the polysaccharide monomer schisanan B separated from schisandra chinensis can serve as a natural PD-L1 + TAMs cell subset activator to be used for treating cancers such as non-small cell lung cancer, intestinal cancer, melanoma, urothelial carcinoma or liver cancer, and the polysaccharide monomer schisanan B has the advantages of being free of toxic and side effects, low in price, wide in adaptive patient population and the like.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a 3-sulfamoyl benzamide compound as well as a preparation method and application thereof. The 3-sulfamoyl benzamide compound has a structure as shown in a formula I. In the formula I, X is chlorine or trifluoromethyl; r1 and R2 are independently C1-4 alkyl or R1, R2 and N atoms connected with R1 and R2 jointly form a heterocyclic group, and the heterocyclic group is a substituted or unsubstituted five-membered or six-membered heterocyclic group; and when the heterocyclic group is a substituted heterocyclic group, the substituent group in the substituted heterocyclic group is one or more of C1-4 alkyl, phenyl and acetyl. The 3-sulfamoyl benzamide compound disclosed by the invention has a remarkable proliferation inhibition effect on HCT116 colon cancer cells, HeLa human cervical cancer cells, MDA-MB-231 human breast cancer cells and A375 human malignant melanoma cells.

The embodiment of the invention provides a melanoma postoperative wound intelligent dressing, and belongs to the technical field of intelligent medical treatment. The intelligent dressing for the wound after the melanoma operation comprises a multiple monitoring module, an intelligent processing module and an on-demand drug delivery module which are arranged on a dressing base body, the multiple monitoring module is used for acquiring biological signals of a wound surface microenvironment in real time; and the intelligent processing unit analyzes the biological signal to generate a wound state judgment result, and controls the on-demand drug delivery module to trigger electrical stimulation or thermal stimulation based on the wound state judgment result so as to realize on-demand drug release. According to the scheme, the deep learning intelligent early warning model fusing the generative adversarial network and the Transform structure is constructed, high-precision analysis and dynamic risk judgment of melanoma postoperative wound multi-dimensional time sequence data are achieved, and the accuracy and stability of wound state recognition are effectively improved.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-6, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-6 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, analgesia, lactation, breast cancer, lung cancer, uterine fibroids, coagulation, etc.

The invention discloses an ultrasonic controllable multifunctional microneedle patch as well as a preparation method and application thereof, and belongs to the technical field of biological materials. The preparation method comprises the following steps: preparing crystalline CoW-LDH nanosheets from Co (NO3) 2.6 H2O, Na2WO4. 2H2O and NaOH, dispersing the crystalline CoW-LDH nanosheets in PBS (Phosphate Buffer Solution), centrifuging and collecting the crystalline CoW-LDH nanosheets, and re-dispersing the crystalline CoW-LDH nanosheets in ultrapure water to obtain amorphous CoW-LDH nanosheets; adding PEG (Polyethylene Glycol), ultrasonically dispersing, stirring at room temperature, centrifuging, collecting and centrifugally washing with ultrapure water to obtain a PEG modified amorphous CoW-LDH nanosheet; and adding microalgae and an amorphous CoW-LDH nanosheet modified by PEG (Polyethylene Glycol) to prepare the ultrasonic controllable multifunctional microneedle patch. The multifunctional microneedle patch disclosed by the invention is high in biological safety, can realize ultrasonic controllability, has a sonodynamic treatment effect and an oxygen supply effect, remarkably inhibits melanoma recurrence and remarkably promotes wound healing, and has a wide application prospect.

The invention provides a docetaxel-loaded platelet delivery system as well as a preparation method and application thereof, and relates to the technical field of medicines. According to the invention, the docetaxel-loaded platelet delivery system is obtained by loading the docetaxel with the platelets for the first time, so that the problem that in the prior art, the traditional docetaxel preparation (injection) needs to be solubilized by polysorbate 80, so that allergy is easily caused is avoided, the safety and biocompatibility of the docetaxel medicine are improved, and the docetaxel-loaded platelet delivery system is suitable for clinical application. And the docetaxel-loaded platelet delivery system has excellent stability and can be stored at normal temperature for a long time. The invention provides the preparation method of the docetaxel-loaded platelet delivery system, and the method is simple to operate, high in encapsulation efficiency and drug loading rate and suitable for popularization. The docetaxel-loaded platelet delivery system disclosed by the invention has an outstanding treatment effect on melanoma and has a good application prospect.

Chimeric antigen receptors for use in treating malignant melanoma and other cancers expressing CS1 are described.

The invention relates to the field of antitumor drugs, in particular to a thiophene acetyl tetrahydro-beta-carboline compound and application thereof. The thiophene acetyl tetrahydro-beta-carboline compound or the pharmaceutically acceptable salt thereof, and the pharmaceutical composition containing the compound can be used for preparing medicines for preventing and / or treating various cancers. The cancer is at least one of breast cancer, lung cancer, osteosarcoma, melanoma, gastric cancer, pancreatic cancer, kidney cancer, glioma and ovarian cancer. Activity screening is carried out on various compounds, it is found for the first time that the 12 compounds provided by the invention have remarkable broad-spectrum inhibitory activity on various human cancer cell lines, and key candidate compounds are provided for developing novel anti-cancer drugs.

This invention belongs to the field of biopharmaceuticals and provides a keratin YK93-8, its encoding nucleic acid molecule, an expression vector containing the nucleic acid molecule, a host cell containing the expression vector or whose genome integrates the nucleic acid molecule, as well as a preparation method and a pharmaceutical composition thereof. It also provides the application of the above-mentioned keratin YK93-8 and other products in the preparation of drugs for treating benign prostatic hyperplasia, lymphoma, melanoma, breast cancer, lung cancer, analgesia, lactation, uterine fibroids, coagulation, etc.

The invention discloses a design method and application of a tyrosinase (TYR) responsive drug for targeted therapy of melanoma, and belongs to the technical field of biological medicines. Based on the biological mechanism that TYR catalyzes tyrosine oxidation, a self-degradation connecting arm drug release strategy is combined, a similar 3-hydroxybenzyl alcohol structure is introduced to simulate a tyrosine substrate, specific recognition and activation of TYR on the drugs are achieved, and the problems that traditional chemotherapeutic drugs are poor in targeting property and serious in adverse reaction are hopefully solved.

The invention discloses application of Bombyx mori neuropeptide BommoOKAtype4 in preparation of a medicine for inhibiting melanoma cell growth, and belongs to the technical field of medical biology. Aiming at the technical problems that melanoma is high in malignancy degree, easy to transfer and limited in treatment means, and whether the bombyx mori neuropeptide BommoOKAtype4 can directly inhibit the growth of melanoma cells is not clear yet when the bombyx mori neuropeptide BommoOKAtype4 is mainly used for skin whitening before, the invention provides the application of the bombyx mori neuropeptide in preparing the medicine for inhibiting the melanoma cells. According to the silkworm neuropeptide, gene expression and protein functions of melanin synthesis key enzymes TYR, TRP1 and TRP2 are comprehensively inhibited by down-regulating expression of a core transcription factor MITF, so that melanoma cell proliferation is directly inhibited while melanin synthesis is inhibited, and therefore, the silkworm neuropeptide can be used for preparing drugs for treating melanoma and has a wide application prospect. A novel peptide candidate substance is provided for treatment of melanoma.

The application belongs to the technical field of biological medicine, and provides application of an NTSR1 inhibitor in preparation of a drug for enhancing the anti-tumor effect of a PD-1 monoclonal antibody, which is combined application of the NTSR1 inhibitor SR48692 and the PD-1 monoclonal antibody in preparation of a drug for treating lung cancer. The application establishes a subcutaneous lung cancer mouse model and a subcutaneous melanoma mouse model, and evaluates the growth inhibition effect of SR48692 on the two kinds of tumor cancer cells; the result shows that the NTSR1 inhibitor SR48692 can achieve the purpose of treating lung cancer and melanoma by inhibiting the growth of cancer cells.

The invention provides lignan, and belongs to the technical field of medicines. According to the invention, a compound shown as a formula I and a compound shown as a formula II are extracted, separated and identified from schisandra chinensis oil for the first time, and the compound shown as the formula I and the compound shown as the formula II are superior to a positive drug group arbutin in the aspect of inhibiting generation of melanin of mouse skin melanoma cells (B16F10); an inflammatory factor release inhibition experiment research shows that the compound shown in the formula I and the compound shown in the formula II have relatively good activity in the aspect of inhibiting LPS-induced mouse mononuclear macrophage RAW264.7 from releasing IL-6 and TNF-alpha; in a skin irritation experiment, the schisandra chinensis non-saponifiable matter containing the compound shown in the formula I and the compound shown in the formula II is non-irritant to the skin of a white rabbit, and it is proved that the compound shown in the formula I and the compound shown in the formula II can be applied to preparation of whitening and anti-inflammatory products. Formula I; formula II.

The invention discloses application of EMSY as a biomarker for predicting melanoma treatment sensitivity and a kit of the EMSY, relates to the technical field of medicines, provides application of the EMSY as the biomarker for predicting the melanoma treatment sensitivity, and provides a new treatment method and a new strategy for clinical intervention and treatment of acra melanoma.

The present application relates to the field of polymer chemistry and biomedical technology, and particularly relates to a macrocyclic lactone polymer shown in formula (I) which is used for preventing or treating hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, gastric cancer, lung cancer, Barrett's esophageal cancer, cervical cancer, pancreatic cancer, endometrial cancer, bone cancer, lymphoma, kidney cancer, brain cancer, nerve cancer, nasopharyngeal cancer, oral cancer, bladder cancer, colorectal cancer and melanoma, and has the potential to be developed into a new type of antitumor drug.

The invention relates to a specific antibody aiming at CD228 protein and an antigen binding fragment thereof, which are used for detecting and treating various tumors, such as melanoma, mesothelioma, colorectal cancer and the like. The antibody binding fragment is helpful for diagnosis and treatment of cancers through specific binding with CD228. The invention further comprises antibody drug conjugates (ADCs) which bind a drug to an antibody through a linker, so as to improve the therapeutic effect and reduce the influence on normal cells. Meanwhile, nucleic acids encoding the antibodies or antigen-binding fragments thereof are provided to produce recombinant antibodies or fragments. Besides, the invention also provides a kit which is used for laboratory research, clinical diagnosis and treatment effect monitoring, is beneficial to determining whether tissues or cells express CD228 or not, and provides a new strategy for personalized and precise treatment of cancers.

The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer associated with FBOX21 mediated p85a ubiquitination such as, for example, cancer (e.g., sarcoma, a carcinoma, a hematological cancer, a solid tumor, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, thyroid cancer, testicular cancer, pancreatic cancer, liver cancer, endometrial cancer, melanoma, a glioma, leukemia, lymphoma, chronic myeloproliferative disorder, myelodysplastic syndrome, myeloproliferative neoplasm, non-small cell lung carcinoma, renal cancer, lung cancer, colon cancer, cervical cancer, and plasma cell neoplasm (myeloma)). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

GD2 specific chimeric antigen receptor effector cells for the treatment of solid tumors, possibly in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor. The invention relates to a GD2-specific chimeric antigen receptor (GD2. CAR) effector cell for use in the treatment of solid tumors, in particular in the treatment of extracranial GD2 + tumors, such as soft tissue sarcoma and osteosarcoma, neuroblastoma, melanoma, lung cancer, bladder cancer and retinoblastoma, and brain tumors. In addition, the present invention also relates to the use of the GD2. CAR genetically modified effector cell in combination with an enhancer of a Zeste homolog 2 (EZH2) inhibitor for the treatment of solid tumors.

Aspects of this invention are related to the use of N-desmethyl ruboxistaurin and pharmaceutically acceptable formulations thereof to modulate RSK signaling. Some aspects of the invention relate to the use of N-desmethyl ruboxistaurin to inhibit RSK. Some aspects of the invention provide methods of using N-desmethyl ruboxistaurin in the treatment of subjects with cancer, including breast cancer, ovarian cancer, prostate cancer, lung cancer, hepatocellular carcinoma, colorectal cancer, melanoma, osteosarcoma, myeloproliferative neoplasms, leukemia, and bladder cancer. The disclosed methods extend beyond disease treatment, including supportive care during radiation chemotherapy and prevention of cancer relapse. N-desmethyl ruboxistaurin administration, alone or in combination with other cancer therapies, inhibits RSK and shows a safety profile that supports its long-term use.

Disclosed are direct-binding dual hypoxia-inducible factor (HIF) inhibitors and their use for treating cancer, including, but not limited to, breast, colorectal, lung, melanoma, pancreatic, and prostate cancer as a monotherapy and in combination with anti-CTLA-4 or anti-PD-1 immunotherapies. The dual HIF inhibitors also can be used for treating diseases, disorders, or conditions associated with ocular neovascularization, including, but not limited to, diabetic macular edema, diabetic retinopathy, and other ischemic retinopathies (including, but not limited to retinal vein occlusion, sickle cell retinopathy, retinopathy of prematurity, Norrie's disease, and Coat's disease), corneal neovascularization, and the treatment or prevention of neurovascular (wet-type) age-related macular degeneration.

A cancer immunotherapy for treating cancers such as melanoma is presented. A method for treating cancer in a subject via administration of anti-LY6E antibody to the subject. The method can further include administering an IFNAR blockade to inhibit type-1 interferon (IFN) signaling, thereby enhancing the ant-tumoral cytotoxic activity of T cells. The IFNAR can include anti-IFNα. The method can also include administering anti-PD1 antibody prior to, commensurate, or after treatment with anti-LY6E. A composition for treating cancer and modulating immune responses in a subject is also included. The composition can include, among other things, the anti-LY6E antibody, the IFNAR blockade, and anti-PD1. The composition and method also present a mechanism to modulate immune response in a subject by preventing upregulation of a Ly6ahigh T-cell subpopulation in response to a stimulus such as cancer, UVB, or interferons.

The invention discloses a preparation method and application of polypeptide hydrogel loaded with modified CAR-T cells and CXCL9, and creatively discovers that the combination of the modified CAR-T cells and the CXCL9 has a remarkable synergistic effect on treatment of melanoma for the first time. According to the invention, efficient enrichment of CAR-T cells at a focus part is realized through the hydrogel delivery system, the local curative effect is improved, in addition, the introduction of CXCL9 further enhances the tumor infiltration capability and the treatment effect of the CAR-T cells, a brand new treatment scheme is provided for tumor treatment, and the clinical application prospect is wide.

This invention provides a chlorambucil NO donor prodrug having the structure shown in Formula (I) or a pharmaceutically acceptable salt thereof: Formula (I). It involves reacting chlorambucil with a dihaloalkane to obtain a halochlorambucil intermediate; reacting the halochlorambucil intermediate with silver nitrate to obtain the chlorambucil NO donor prodrug. This invention applies the chlorambucil NO donor prodrug to the preparation of drugs for treating tumors, such as melanoma, lymphoma, leukemia, or breast cancer. This nanosystem exhibits good NO release levels under light irradiation. Cellular experiments have demonstrated its good antitumor effect, providing a new strategy for multimodal combined antitumor therapy.

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases in a subject, wherein the proliferative diseases include cancer, benign neoplasm, angiogenesis, inflammatory disease, autoinflammatory disease, and autoimmune disease, and the cancer includes leukemia, melanoma, multiple myeloma. Treatment of a subject having a proliferative disease with the compounds or compositions of the present invention can inhibit abnormal activity of cyclin-dependent kinase 7, thus inducing apoptosis and / or inhibiting transcription in the subject.

Disclosed are Schistosoma japonicum eggs and the ingredients of secretions and excretions thereof, comprising eggs, egg culture supernatant, and egg secreted proteins. (hereinafter referred to as “Schistosoma eggs and secretions and excretions thereof” for short). A Schistosoma infection can significantly inhibit metastatic tumors of organs such as lungs, and an anti-tumor effect is mediated by the “Schistosoma eggs and secretions and excretions thereof”, which have the effect of inhibiting various host tumors, comprising lung cancer, liver cancer, melanoma, and hematological tumors. Two egg secreted proteins having an anti-tumor effect are further identified. The “Schistosoma eggs and secretions and excretions thereof” exert an anti-tumor effect by activating natural immunity such as alveolar macrophages. The “Schistosoma eggs and secretions and excretions thereof” have a potential application value in prevention and treatment of tumors in humans.

The present invention relates to the therapeutic treatment of skin cancer, in particular melanoma, by using rubitecan, PM14 (ecubectedin) and compound IA.

The disclosure provides methods for inhibiting: tyrosinase function and / or regulation or its activity, melanogenesis, melanin production, and cell proliferation of melanomas using compounds described here, or analog(s) thereof, or compositions comprising such compounds or analog(s) thereof in a therapeutically effective amount to bind or occupy any one or more of the tyrosinase binding sites in an amount sufficient to inhibit tyrosinase (i.e., function or regulation) or its activity, inhibit melanogenesis, inhibit melanin production, even out skin pigmentation or skin tone, brighten skin pigmentation or skin tone, inhibit cell proliferation of melanomas, and ameliorate or treat skin cancer (e.g., melanoma) in a subject in need thereof.

Phytol (PHY) is a metabolite of plant chlorophyll, is wide in source and is a chain-like diterpenoid substance consisting of four isoprene units, and the phytol ingested by animals is subjected to oxidative metabolism in vivo, so that not only can energy be provided for the animals, but also the growth of the animals can be promoted, and the growth of the animals can be promoted. Moreover, the phytol and the phytanic acid metabolite of the phytol can also be used as signal molecules to participate in glycolipid metabolism and adipocyte differentiation regulation processes, but people cannot directly take the phytol and the phytanic acid from the nature. The effect of phytol in the generation and development of tumors still has huge unknown property. According to the research, the influence of the phytol and the derivative thereof on the growth of colon cancer, breast cancer and melanoma is detected through an in-vitro experiment CCK-8 (Cell Count Kit 8) and an in-vivo experiment such as a mouse subcutaneous tumor model, and the phytol and the derivative thereof are found to be capable of remarkably inhibiting the growth of colon cancer, breast cancer and melanoma and have no obvious toxic and side effects on heart, liver and kidney functions.

Disclosed are methods for detecting and treating cancers (such as carcinoma, leukemia, lung cancer, colon cancer, central nervous system (CNS) cancer, melanoma, ovarian cancer, renal cancer, oral cancer, prostate cancer and / or breast cancer). The method may include receiving a sample from a patient (such as a sample from a biopsy, a sample from an extracellular vesicle, or a sample from a circulating tumor cell). The method may include determining whether a LY6C protein or a phosphorylated ANXA2 protein is detected in the sample. The method may include treating a patient for cancer by targeting the LY6C protein when the LY6C protein is detected (e.g., using photoimmunotherapy (PIT) or near infrared photoimmunotherapy (NIR-PIT)). or treating a patient for cancer by targeting an ANXA2 protein (e.g, using inhibitors, decoys, etc.) when the phosphorylated ANXA2 protein is detected.

The present application provides a polypeptide or a pharmaceutically acceptable salt thereof, wherein the polypeptide has an amino acid sequence as shown in SEQ ID NO: 1. The polypeptide or the pharmaceutically acceptable salt thereof can bind to PD-1 and CTLA-4, and is used for effectively inhibiting PD-1 and CTLA-4. Thus, the polypeptide or the pharmaceutically acceptable salt thereof can be used for detecting PD-1 and / or CTLA-4, and can also be used for treating or preventing diseases mediated by PD-1 and / or CTLA-4 (such as tumors or cancers, for example, lung cancer, melanoma, lymphoma, leukemia and other diseases involving tumor immune escape).